Cargando…

Fertility and Obstetric Outcomes of Assisted Reproductive Technology (ART) in Women With Adenomyosis Following Gonadotropin-Releasing Hormone Agonist Therapy: A Single-Center Experience

Introduction: Adenomyosis is an ambiguous disorder causing a wide variety of implications from dysmenorrhea, heavy menstrual bleeding, and infertility to pregnancy complications. Adenomyosis is associated with altered endocrine and inflammatory milieu, resulting in impaired implantation and reduced...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, Asha R, Duraikannan, Uthra Priyadarshini, Rao, Damodar R, Giridhar, Padmashri, Chinnasamy, Sivakumar N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552683/
https://www.ncbi.nlm.nih.gov/pubmed/37809195
http://dx.doi.org/10.7759/cureus.44691
_version_ 1785116010794188800
author Rao, Asha R
Duraikannan, Uthra Priyadarshini
Rao, Damodar R
Giridhar, Padmashri
Chinnasamy, Sivakumar N
author_facet Rao, Asha R
Duraikannan, Uthra Priyadarshini
Rao, Damodar R
Giridhar, Padmashri
Chinnasamy, Sivakumar N
author_sort Rao, Asha R
collection PubMed
description Introduction: Adenomyosis is an ambiguous disorder causing a wide variety of implications from dysmenorrhea, heavy menstrual bleeding, and infertility to pregnancy complications. Adenomyosis is associated with altered endocrine and inflammatory milieu, resulting in impaired implantation and reduced fertility potential. It is also associated with increased incidence of obstetric complications such as miscarriage, antepartum hemorrhage, placental mal-position, hypertensive disorders, small for gestational age-intrauterine growth restriction (SGA-IUGR), cesarean section, preterm labor, preterm premature rupture of membranes (PPROM), and neonatal intensive care unit (NICU) admissions. Objective: The aim of our study was to investigate the fertility and obstetric outcomes in women with adenomyosis treated with GnRH agonists compared to controls with normal uteri undergoing in-vitro fertilization (IVF) at our center, thereby establishing the role of gonadotropin-releasing hormone (GnRH) agonists in managing sub-fertile women with adenomyosis. Materials and methods: We carried out a retrospective cohort study at our hospital to analyze the effects of adenomyosis on IVF and pregnancy outcomes. This study (n=83) involves women with adenomyosis between the ages of 21 and 37 years who were followed up at our center between 2013 and 2022. The controls (n=83) were selected from women who underwent IVF-intracytoplasmic sperm injection (IVF-ICSI) for tubal or mild male factor infertility with normal appearing uterus within the same time frame. Women with adenomyosis were given GnRH agonist as long/ultralong agonist protocol before controlled ovarian stimulation or as down-regulated frozen embryo transfer (FET). The length of suppression was between one and six months based on the size of the uterus and response to treatment. Fertility and obstetric outcomes were analyzed. Results: The implantation rates were found to be equivocal: 54.2% and 53% in the adenomyosis and control groups, respectively (p=0.208). The cumulative live birth rate was 50.6% and 48.2% in the study and control groups, respectively (p=0.341). The biochemical pregnancy rate and the first- and second-trimester miscarriage rates were not significantly different between the group with adenomyosis and the group with normal uterus. The incidence of preterm deliveries and antepartum hemorrhage was found to be significantly increased in the study group. Conclusion: Medical management in women with adenomyosis optimizes the live birth rates giving results at par with the control population.
format Online
Article
Text
id pubmed-10552683
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-105526832023-10-06 Fertility and Obstetric Outcomes of Assisted Reproductive Technology (ART) in Women With Adenomyosis Following Gonadotropin-Releasing Hormone Agonist Therapy: A Single-Center Experience Rao, Asha R Duraikannan, Uthra Priyadarshini Rao, Damodar R Giridhar, Padmashri Chinnasamy, Sivakumar N Cureus Endocrinology/Diabetes/Metabolism Introduction: Adenomyosis is an ambiguous disorder causing a wide variety of implications from dysmenorrhea, heavy menstrual bleeding, and infertility to pregnancy complications. Adenomyosis is associated with altered endocrine and inflammatory milieu, resulting in impaired implantation and reduced fertility potential. It is also associated with increased incidence of obstetric complications such as miscarriage, antepartum hemorrhage, placental mal-position, hypertensive disorders, small for gestational age-intrauterine growth restriction (SGA-IUGR), cesarean section, preterm labor, preterm premature rupture of membranes (PPROM), and neonatal intensive care unit (NICU) admissions. Objective: The aim of our study was to investigate the fertility and obstetric outcomes in women with adenomyosis treated with GnRH agonists compared to controls with normal uteri undergoing in-vitro fertilization (IVF) at our center, thereby establishing the role of gonadotropin-releasing hormone (GnRH) agonists in managing sub-fertile women with adenomyosis. Materials and methods: We carried out a retrospective cohort study at our hospital to analyze the effects of adenomyosis on IVF and pregnancy outcomes. This study (n=83) involves women with adenomyosis between the ages of 21 and 37 years who were followed up at our center between 2013 and 2022. The controls (n=83) were selected from women who underwent IVF-intracytoplasmic sperm injection (IVF-ICSI) for tubal or mild male factor infertility with normal appearing uterus within the same time frame. Women with adenomyosis were given GnRH agonist as long/ultralong agonist protocol before controlled ovarian stimulation or as down-regulated frozen embryo transfer (FET). The length of suppression was between one and six months based on the size of the uterus and response to treatment. Fertility and obstetric outcomes were analyzed. Results: The implantation rates were found to be equivocal: 54.2% and 53% in the adenomyosis and control groups, respectively (p=0.208). The cumulative live birth rate was 50.6% and 48.2% in the study and control groups, respectively (p=0.341). The biochemical pregnancy rate and the first- and second-trimester miscarriage rates were not significantly different between the group with adenomyosis and the group with normal uterus. The incidence of preterm deliveries and antepartum hemorrhage was found to be significantly increased in the study group. Conclusion: Medical management in women with adenomyosis optimizes the live birth rates giving results at par with the control population. Cureus 2023-09-04 /pmc/articles/PMC10552683/ /pubmed/37809195 http://dx.doi.org/10.7759/cureus.44691 Text en Copyright © 2023, Rao et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Endocrinology/Diabetes/Metabolism
Rao, Asha R
Duraikannan, Uthra Priyadarshini
Rao, Damodar R
Giridhar, Padmashri
Chinnasamy, Sivakumar N
Fertility and Obstetric Outcomes of Assisted Reproductive Technology (ART) in Women With Adenomyosis Following Gonadotropin-Releasing Hormone Agonist Therapy: A Single-Center Experience
title Fertility and Obstetric Outcomes of Assisted Reproductive Technology (ART) in Women With Adenomyosis Following Gonadotropin-Releasing Hormone Agonist Therapy: A Single-Center Experience
title_full Fertility and Obstetric Outcomes of Assisted Reproductive Technology (ART) in Women With Adenomyosis Following Gonadotropin-Releasing Hormone Agonist Therapy: A Single-Center Experience
title_fullStr Fertility and Obstetric Outcomes of Assisted Reproductive Technology (ART) in Women With Adenomyosis Following Gonadotropin-Releasing Hormone Agonist Therapy: A Single-Center Experience
title_full_unstemmed Fertility and Obstetric Outcomes of Assisted Reproductive Technology (ART) in Women With Adenomyosis Following Gonadotropin-Releasing Hormone Agonist Therapy: A Single-Center Experience
title_short Fertility and Obstetric Outcomes of Assisted Reproductive Technology (ART) in Women With Adenomyosis Following Gonadotropin-Releasing Hormone Agonist Therapy: A Single-Center Experience
title_sort fertility and obstetric outcomes of assisted reproductive technology (art) in women with adenomyosis following gonadotropin-releasing hormone agonist therapy: a single-center experience
topic Endocrinology/Diabetes/Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552683/
https://www.ncbi.nlm.nih.gov/pubmed/37809195
http://dx.doi.org/10.7759/cureus.44691
work_keys_str_mv AT raoashar fertilityandobstetricoutcomesofassistedreproductivetechnologyartinwomenwithadenomyosisfollowinggonadotropinreleasinghormoneagonisttherapyasinglecenterexperience
AT duraikannanuthrapriyadarshini fertilityandobstetricoutcomesofassistedreproductivetechnologyartinwomenwithadenomyosisfollowinggonadotropinreleasinghormoneagonisttherapyasinglecenterexperience
AT raodamodarr fertilityandobstetricoutcomesofassistedreproductivetechnologyartinwomenwithadenomyosisfollowinggonadotropinreleasinghormoneagonisttherapyasinglecenterexperience
AT giridharpadmashri fertilityandobstetricoutcomesofassistedreproductivetechnologyartinwomenwithadenomyosisfollowinggonadotropinreleasinghormoneagonisttherapyasinglecenterexperience
AT chinnasamysivakumarn fertilityandobstetricoutcomesofassistedreproductivetechnologyartinwomenwithadenomyosisfollowinggonadotropinreleasinghormoneagonisttherapyasinglecenterexperience